BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 19523934)

  • 1. A truncated minimal-E1a gene with potency to support adenoviral replication mediates antitumor activity by down-regulating Neu expression and preserving Rb function.
    Fang L; Huang Y; Hu X; Sun L; He X; Hu H; Pu Y; Cao X; Luo H; Pan S; Gu J; Su C
    Chem Biol Interact; 2009 Sep; 181(1):1-7. PubMed ID: 19523934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
    Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
    Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
    Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
    Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
    J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice.
    Su C; Peng L; Sham J; Wang X; Zhang Q; Chua D; Liu C; Cui Z; Xue H; Wu H; Yang Q; Zhang B; Liu X; Wu M; Qian Q
    Mol Ther; 2006 May; 13(5):918-27. PubMed ID: 16497559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of retinoblastoma in vitro and in vivo with conditionally replicating oncolytic adenovirus H101.
    Song X; Zhou Y; Jia R; Xu X; Wang H; Hu J; Ge S; Fan X
    Invest Ophthalmol Vis Sci; 2010 May; 51(5):2626-35. PubMed ID: 20007825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
    Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
    Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo.
    Alonso MM; Cascallo M; Gomez-Manzano C; Jiang H; Bekele BN; Perez-Gimenez A; Lang FF; Piao Y; Alemany R; Fueyo J
    Cancer Res; 2007 Sep; 67(17):8255-63. PubMed ID: 17804740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
    Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor.
    Cho WK; Seong YR; Lee YH; Kim MJ; Hwang KS; Yoo J; Choi S; Jung CR; Im DS
    Mol Ther; 2004 Nov; 10(5):938-49. PubMed ID: 15509511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication.
    Kamizono J; Nagano S; Murofushi Y; Komiya S; Fujiwara H; Matsuishi T; Kosai K
    Cancer Res; 2005 Jun; 65(12):5284-91. PubMed ID: 15958575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer.
    Maemondo M; Saijo Y; Narumi K; Kikuchi T; Usui K; Tazawa R; Matsumoto K; Nakamura T; Sasaki K; Takahashi M; Niitsu Y; Nukiwa T
    Cancer Res; 2004 Jul; 64(13):4611-20. PubMed ID: 15231673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region.
    Saito Y; Sunamura M; Motoi F; Abe H; Egawa S; Duda DG; Hoshida T; Fukuyama S; Hamada H; Matsuno S
    Cancer Gene Ther; 2006 Mar; 13(3):242-52. PubMed ID: 16179928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer.
    Fukuda K; Abei M; Ugai H; Kawashima R; Seo E; Wakayama M; Murata T; Endo S; Hamada H; Hyodo I; Yokoyama KK
    Cancer Gene Ther; 2009 Feb; 16(2):126-36. PubMed ID: 18818710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conditionally replicating adenovirus-mediated gene therapy in bladder cancer: an orthotopic in vivo model.
    Melquist JJ; Kacka M; Li Y; Malaeb BS; Elmore J; Baseman AG; Hsieh JT; Koeneman KS
    Urol Oncol; 2006; 24(4):362-71. PubMed ID: 16818192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.